Solidago

by | Mar 21, 2018 | Solidago

How Can We Help?
You are here:
< Back

EA-1356 is an organophosphate nerve agent of the G-series.[2][3] It is highly resistant to enzymatic degradation in the body. [4] The nerve agent was tested at Edgewood Arsenal in Maryland (the "EA" in "EA-1356") among many other chemicals tested on humans. A novel enzyme was patented by the US Army in 2018 to break down EA-1356. It is a schedule 1 substance by the Chemical Weapons Convention standards. It is under the category of munitions of ML7.b.1.a.

References

  1. ^ Noga, M.; Michalska, A.; Jurowski, K. (2024). "The estimation of acute oral toxicity (LD(50)) of G-series organophosphorus-based chemical warfare agents using quantitative and qualitative toxicology in silico methods". Archives of Toxicology. doi:10.1007/s00204-024-03714-5. PMID 38493428.
  2. ^ Söderström MT, Ketola RA, Kostiainen O (1995). "Identification of some nerve agent homologues and dialkyl methylphosphonates by gas chromatography/Fourier transform infrared spectrometry". Fresenius' Journal of Analytical Chemistry. 352 (6): 550–556. doi:10.1007/BF00323072. S2CID 100910978.
  3. ^ Ellison DH (2008). Handbook of Chemical and Biological Warfare Agents (Second ed.). CRC Press. ISBN 978-0-849-31434-6.
  4. ^ US 10124043, Harvey SP, Guelta MA, McMahon LR, "Mutant OPAA enzymes with increased catalytic efficiency on organophosphorus compound EA1356", issued 13 November 2018, assigned to U.S. Army Edgewood Chemical Biological Center 
Categories
Table of Contents